This article contains content that is written like
an advertisement. (September 2019) |
Company type | Private |
---|---|
Industry | Information technology |
Founded | 2007 |
Fate | Acquired by Tute Genomics, Inc. in 2015 (which later becomes a subsidiary of PierianDX, Inc. in 2016) |
Headquarters | , |
Key people |
|
Services | Human genome interpretation |
Knome, Inc. was a human genome interpretation company based in Cambridge, Massachusetts. Launched in 2007, Knome focused on improving quality of life by applying insights gained from the interpretation of human genomes. They helped identify and classify the variants, genes, and gene sets that are likely to govern or underlie a specific disease, tumor, or drug response. Their clients included academic, pharmaceutical and medical researchers. In 2015, it was acquired by Tute Genomics. [1]
Knome developed technologies that automated many of the manual tasks involved in interpreting whole human genomes. These technologies were designed to address the informatics and workflow bottlenecks that typically hinder whole genome interpretation. The company's core technology, kGAP, was developed in 2009 and served as the foundation for a number of Knome's products and services including the knoSYS® platform.
For academic, pharmaceutical, and medical researchers, Knome offered:
This article contains content that is written like
an advertisement. (September 2019) |
Company type | Private |
---|---|
Industry | Information technology |
Founded | 2007 |
Fate | Acquired by Tute Genomics, Inc. in 2015 (which later becomes a subsidiary of PierianDX, Inc. in 2016) |
Headquarters | , |
Key people |
|
Services | Human genome interpretation |
Knome, Inc. was a human genome interpretation company based in Cambridge, Massachusetts. Launched in 2007, Knome focused on improving quality of life by applying insights gained from the interpretation of human genomes. They helped identify and classify the variants, genes, and gene sets that are likely to govern or underlie a specific disease, tumor, or drug response. Their clients included academic, pharmaceutical and medical researchers. In 2015, it was acquired by Tute Genomics. [1]
Knome developed technologies that automated many of the manual tasks involved in interpreting whole human genomes. These technologies were designed to address the informatics and workflow bottlenecks that typically hinder whole genome interpretation. The company's core technology, kGAP, was developed in 2009 and served as the foundation for a number of Knome's products and services including the knoSYS® platform.
For academic, pharmaceutical, and medical researchers, Knome offered: